Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes

Diabetes and Metabolism

Volumn 35, Issue 6, 2009, Pages 484-489

  Hermans, Michel P ^a   Ahn, Sylvie A ^a   Rousseau, Michel F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Albuminuria; Coronary artery disease; Diabetes; Erectile dysfunction; Retinopathy; Stroke

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN;

ALBUMINURIA; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE DURATION; ERECTILE DYSFUNCTION; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PENIS ERECTION; POLYNEUROPATHY; PREVALENCE; QUESTIONNAIRE; RETINOPATHY; SMOKING; STROKE; WAIST CIRCUMFERENCE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GREAT BRITAIN; HUMANS; IMPOTENCE, VASCULOGENIC; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK; SEVERITY OF ILLNESS INDEX;

EID: 71349084119     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.06.003     Document Type: Article

References (22)

1. Chung W.S., Sohn J.H., and Park Y.Y. Is obesity an underlying factor in erectile dysfunction?. Eur Urol 36 (1999) 68-70
2. Esposito K., Giugliano F., Martedì E., Feola G., Marfella R., D'Armiento M., et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabet Care 28 (2005) 1201-1203
3. El Melegy N.T., Ali M.E., and Awad E.M. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 96 (2005) 1079-1086
4. Trussell J., and Legro R. Erectile dysfunction: does insulin resistance play a part?. Fertil Steril 88 (2007) 771-778
5. Ma R.C., So W.Y., Yang X., Yu L.W., Kong A.P., Ko G.T., et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 51 (2008) 2045-2050
6. Aversa A., Vitale C., Volterrani M., Fabbri A., Spera G., Fini M., et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 25 (2008) 37-44
7. Wheatcroft S.B., Williams I.L., Shah A.M., and Kearney M.T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 20 (2003) 255-268
8. Kim J.-A., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
9. Hermans M.P., Ahn S.A., Gruson D., and Rousseau M.F. The metabolic syndrome phenotype is associated with raised circulating Big endothelin-1 independently of coronary artery disease in type 2 diabetes. Diab Met Syndr Clin Res Rev 1 (2007) 229-237
10. Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., and Peña B.M. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11 (1999) 319-326
11. Stevens R.J., Coleman R.L., Adler A.I., Stratton I.M., Matthews D.R., and Holman R.R. UKPDS, 66, risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes. Diabet Care 27 (2004) 201-207
12. Hermans M.P., Ahn S., and Rousseau M.F. Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. Diab Metab Syndr Clin Res Rev 2 (2008) 93-98
13. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
14. Munoko T.N., and Hermans M.P. Phenotypic characterization of first generation Maghrebian migrants with type 2 diabetes: A gender-based comparison with a reference North-Caucasian Belgian cohort. Diab Met Syndr Clin Res Rev 2 (2008) 115-124
15. Hermans MP, Ahn SA, Rousseau MF. Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea. Diab Met Syndr Clin Res Rev 2009;3:50-4.
16. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
17. Levy J.C., Matthews D.R., and Hermans M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabet Care 21 (1998) 2191-2192
18. Hermans M.P., Levy, Morris R.J., and Turner R.C. Comparison of insulin sensitivity tests across a range of glucose tolerance form normal to diabetes. Diabetologia 42 (1999) 678-687
19. Hermans M.P. Diabetic macro- and microvascular disease in type 2 diabetes. Diabet Vasc Dis Res 4 (2007) S7-S11
20. Dehout F., Haumont S., Gaham N., Amoussou-Guenou K.D., and Hermans M.P. Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: Prevalence, gender differences and HOMA hyperbolic product. Diab Met Syndr Clin Res Rev 2 (2008) 5-11
21. Alexopoulou O., Jamart J., Maiter D., Hermans M.P., De Hertogh R., De Nayer P., et al. Erectile dysfunction and lower androgenicity in type 1 diabetic patients. Diabet Metab 27 (2001) 329-336
22. Fruchart J.-C., Sacks F., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabet Vasc Dis Res 5 (2008) 319-335